[
  {
    "ts": "2026-02-01T10:05:49+00:00",
    "headline": "Amgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook",
    "summary": "Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab. The decision is tied to portfolio prioritization and returns full program control to Kyowa Kirin. The move signals a shift in Amgen’s focus within its dermatology and autoimmune pipeline. For you as an investor, this development sits at the intersection of immunology, dermatology and large molecule drug development. These are areas where Amgen has been active across multiple...",
    "url": "https://finance.yahoo.com/news/amgen-refocuses-pipeline-rocatinlimab-exit-100549916.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c89c6bc2-0048-3ee5-8c17-95420921f462",
      "content": {
        "id": "c89c6bc2-0048-3ee5-8c17-95420921f462",
        "contentType": "STORY",
        "title": "Amgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook",
        "description": "",
        "summary": "Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab. The decision is tied to portfolio prioritization and returns full program control to Kyowa Kirin. The move signals a shift in Amgen’s focus within its dermatology and autoimmune pipeline. For you as an investor, this development sits at the intersection of immunology, dermatology and large molecule drug development. These are areas where Amgen has been active across multiple...",
        "pubDate": "2026-02-01T10:05:49Z",
        "displayTime": "2026-02-01T10:05:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-refocuses-pipeline-rocatinlimab-exit-100549916.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-refocuses-pipeline-rocatinlimab-exit-100549916.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "KYKOF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]